Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Hopes To Reach Market First For Pre-Metastatic Prostate Cancer With Apalutamide

Executive Summary

Janssen hasn’t released Phase III data yet but says the next-generation androgen receptor inhibitor showed potential benefit for metastasis-free survival.


Related Content

How The Prostate Cancer Market Will Look Over Next Decade
J&J To Get EU Fast-Track Decision On Apalutamide
PTAB Clears Path For Earlier Generic Zytiga Launch
J&J Immunology Growth Now Hinges On Stelara, Tremfya After RA Setback
Pfizer Poised To PROSPER From Xtandi In Expanded Indication
Janssen's Zytiga Shines At ASCO But Prostate Cancer Pipeline Progress May Dampen Impact
Xtandi Sales Disappoint Pfizer, Returning Focus To The High-Priced Deal


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts